June 2004 HITCH Training Slide Set #3 Special Considerations in Antiretroviral Therapy.

Slides:



Advertisements
Similar presentations
TB & HIV Infection: Treatment
Advertisements

TB Disease and Latent TB Infection
Tuberculosis – The facts!
Cross-sectional assessment of patient outcomes using a systematic file review process Ambereen Jaffer, Gesine Meyer-Rath, Malebo Maponyane, Aimee Malingan,
1 M&E and ART programme Sri Lanka. 2 Overview of the presentation 1.NSACP service delivery points 2.Reporting units of ART programme 3.Recording and reporting.
USING SLFS TUBERCULOSIS SYMPTOM SCREENING TOOL FOR ADULTS A How To Guide.
MiMOSA Training 1. Opening 2. TB WRx and the 2007 DS Forms 3. Data entry and report generation for the new DS forms 4. Mission settings for DS Forms 5.
W. J. Fenton MD, FRCPC, FACP Clinical Professor of Medicine, U of S TB 101 for Primary Care Providers.
Review of HIV and Opportunistic Infections (OI) in Children
World Health Organization TB Case Definitions
International Standards of Tuberculosis Care Implementation by Pulmonologists in Private Practice in Jakarta E. Burhan 1, M. A. Nawas 1, D. Kusumo Sutoyo.
Interim analysis of a double- blind, placebo-controlled study with TMC207 in patients with Multi-Drug Resistant (MDR) Tuberculosis Karel de Beule, CDTL.
In the name of God Fariba Rezaeetalab Assistant Professor.
Unit 10 Treating the Dually Infected Patient: B Family Case Botswana National Tuberculosis Programme Manual Training for Medical Officers.
TB. Areas of Concern TB cases continue to be reported in every state Drug-resistant cases reported in almost every state Estimated million persons.
Why do we test? 1.We want to prevent an outbreak of Tuberculosis in our campus community 2.We want to find those that are affected and get them treated.
Diagnosis of TB.
Policy review of HIV and TB guidelines for high HIV/TB burden African countries HIV/AIDS Department World Health Organization.
* TB is caused by a bacterium called Mycobacterium Tuberculosis. The bacteria usually attacks the lungs, but TB bacteria can attack any part of the.
Tuberculosis Presented by Vivian Pham and Vivian Nguyen.
Unit 5: IPT Isoniazid TB Preventive Therapy
Plans for Diagnosis and Management of Acute Pyelonephritis.
“Don’t tell me TB is under control!” Understanding TB
IAS–USA When to Start Antiretroviral Therapy Constance A. Benson, MD Professor of Medicine University of California San Diego FINAL: Presented.
1 First Clinic Visit for Patients with HIV Infection HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Unit 6 Diagnosing TB: B Family Case Botswana National Tuberculosis Programme Manual Training for Medical Officers.
Tuberculosis Research of INA-RESPOND on Drug-resistant
Tuberculosis Egan’s Chapter 22. Mosby items and derived items © 2009 by Mosby, Inc., an affiliate of Elsevier Inc. 2 Tuberculosis (TB) The incidence of.
Treatment of Tuberculosis: New Case Case Studies Module 7A2 – March 2010.
TUBERCULOSIS: THE LINKS WITH POVERTY Anthony D Harries The Union, Paris, France.
Screening for TB.
1 Monitoring The Patient on ARV Treatment HAIVN Harvard Medical School AIDS Initiative in Vietnam.
TB-HIV INTEGRATION IN THE WORKPLACE 2 nd Private Sector Conference on HIV and AIDS Presenter: Dr S Charalambous.
HIV/TB – Case Studies David Schlossberg, MD, FACP Medical Director, TB Control Program Philadelphia Department of Health.
Welcome to I-TECH HIV/AIDS Clinical Seminar Series November 19, 2009 Tuberculosis in Persons with HIV/AIDS: Opportunities for Prevention Charles Nolan,
1 HIV Clinical Staging HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Tuberculosis Case Study Presenter Xoliswa Poswa TB Laboratory, NHLS/CMID.
Module 2 TB Disease Transmission & Prevention. Pulmonary Tuberculosis Extra -Pulmonary TB an infectious disease caused by a microorganism called Mycobacterium.
A Self Study Powerpoint
Human Immunodeficiency Virus (HIV) This virus causes HIV infection and AIDS The HIV infected person may, or may not have AIDS. They may, or may not, have.
Unit 5 Isoniazid Prevention Therapy: B Family Case Botswana National Tuberculosis Programme Manual Training for Medical Officers.
Module 3: Management of Patients on Antiretroviral Therapy Unit 2: Initiation and Monitoring of ART in Adults and Adolescents.
Prophylaxis of Opportunistic Infections
Unit 11 Drug Resistance and MDR-TB: B Family Case Botswana National Tuberculosis Programme Manual Training for Medical Officers.
Integration of TB and HIV Screening, Care and Treatment in Mulago Hospital, Uganda Rhoda Wanyenze, Doris Mwesigire, Henry Luzze, Violet Gwokyalya, Julius.
Scale up TB/HIV activities in Asia Pacific 8-9Aug09 1 TB/HIV collaborative activities in Thailand Sriprapa Nateniyom, M.D. TB Bureau, Department of Disease.
1 Communicating to Other Health Professionals About Your Patient: Doing Case Presentations HAIVN Harvard Medical School AIDS Initiative in Vietnam.
By: Mpho Kontle and Topo Moses. Introduction & Etiology Multi-drug-resistant tuberculosis (MDR-TB) is defined as tuberculosis that is resistant to at.
Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
LEARNING MODULE TITLE SUBTITLE. HISTORY OF PRESENT ILLNESS An 18 year-old woman with no past medical history and no known risks for TB presents with several.
Response to Antiretroviral Treatment In an Ethiopian Hospital Samuel Hailemariam, MD, MPH; J Allen McCutchan, MD, MSc Meaza Demissie, MD, PMH, PHD; Alemayehu.
Roundtable. Detection and treatment of TB Andrew Black.
Tuberculosis in Children: Treatment and Monitoring Module 10B - March 2010.
EPIDEMIOLOGY OF PULMONARY TUBERCULOSIS. LEARNIN G OBJECTIVES State the diagnostic criteria of pulmonary tuberculosis Describe trend & state reasons for.
Important diseases and their global impact Objectives To be able to describe the causes and means of transmission of malaria, AIDS/HIV and T.B To be able.
Sarah Al-Obaydi M.B.Ch.B, MPH(c) Fulbright scholar.
Initiative taken by Health Camp
Infant clinical considerations
This is an archived document.
Predictors of antiretroviral treatment associated tuberculosis in Ethiopia: a nested case control study Nebiyu Mesfin, MD.
William Burman Denver Public Health Tuberculosis Trials Consortium
Dr Dawood Quiz questions.
This is an archived document.
Epidemiology of pulmonary tuberculosis
Presentation 10 Analysing results and defining cases
World Health Organization
Volume 375, Issue 9709, Pages (January 2010)
Surveillance for TB in HIV Care and Treatment Settings (CTS)
Presented by: Dr. Letshufi DSV 04th August 2016 Pretoria
Presentation transcript:

June 2004 HITCH Training Slide Set #3 Special Considerations in Antiretroviral Therapy

Objectives This lecture will provide information on the following subjects:  Tuberculosis (TB) and antiretroviral (ARV) drug therapy  Immune reconstitution syndrome  Adherence  Clinical and laboratory monitoring for patients in South Africa on antiretroviral treatment (ART) regimens

Concomitant Tuberculosis

Evaluate patients for TB before starting ART  Suspect TB if 2 or more of the following are present:  Observed weight loss of ≥1.5 kg over the past 4 weeks  Cough >2 weeks  Night sweats >2 weeks  Fever >2 weeks  If patient has symptoms suggestive of TB, collect 2 sputum specimens for 2 smears and a TB culture

Patient Presents with TB before Commencing ART  If no history of WHO Stage IV illness, and CD4 count >200 cells/µL, ART is not yet needed.  Start TB treatment and reassess need for ART after completion of TB treatment.  If history of WHO Stage IV illness and/or CD4 count <200 cells/µL:  Complete 2 months of TB therapy before commencing ART.

Patient Presents with TB before Commencing ART (cont.)  If CD4 count is <50 cells/µL or other serious HIV- related illness is present, make sure that the patient is tolerating TB treatment before initiating ART.  Complete at least 2 weeks of TB treatment before initiating ART.  Start patient on first-line therapy consisting of stavudine (d4T), lamivudine (3TC), and efavirenz (EFV).

Patient Develops TB while on ART  ART should be continued throughout TB treatment, with:  monitoring of clinical status  changes to drug regimens as needed to compensate for drug-drug interactions

Patient Taking TB Medication and ARVs Concurrently  Avoid nevirapine (NVP) in ARV drug regimen.  ARV drug concentrations may decrease as a result of TB medication.  There will be an increased risk for hepatotoxicity.  Patients on TB medication and ARVs are taking a large number of tablets: do proactive counseling to improve adherence.

If TB Patient Is on ARV Regimen 1b  Change NVP to EFV whenever possible.  If not possible (eg, EFV intolerance or significant risk of pregnancy), NVP may be continued in selected cases, with monthly liver enzyme monitoring.  Discuss these cases with an ARV expert.

If TB Patient Is on ARV Regimen 2  Change lopinavir/ritonavir dosage to 400/400 mg (3 extra caps of ritonavir) every 12 hours.  Continue until 2 weeks after completion of TB treatment, when the extra ritonavir can be stopped.

Immune Reconstitution Syndrome

 As immune system is strengthened by ART, it may begin to aggressively fight coexisting opportunistic infections (OIs).  If immune system response is too vigorous, it causes inflammation of tissues involved in the infection.  This response makes coexisting OIs worse.  This is called immune reconstitution syndrome or immune reconstitution disease.

Immune Reconstitution Syndrome (cont.)  Can occur with TB, cryptococcosis, and cytomegalovirus (CMV), among other infections.  Symptoms: fever, sweats, weight loss, cough, decreased visual sharpness (in CMV), enlarged lymph nodes (in TB).  Often seen in patients with advanced HIV disease: low CD4 T-cell count (<50 cells/µL).  Develops in the initial weeks of ART.

Immune Reconstitution Syndrome (cont.)  Immune reconstitution syndrome is not a sign of treatment failure.  Not a reason to switch therapy but should be evaluated thoroughly to exclude treatment failure or infections.  In severe cases, patients should be referred to an expert.  There are no clear guidelines for the management of immune reconstitution syndrome.  Approaches include stopping ARVs or using systemic corticosteroid treatment in severe cases.

Prophylaxis of Opportunistic Infections

 Cotrimoxazole to prevent Pneumocystis jiroveci pneumonia (PCP) and toxoplasmosis must be continued in all patients on ART until CD4 count remains >200 cells/µL.  Also recommended if CD4 count drops to <200 cells/µL, as in cases of treatment failure.  Fluconazole for patients who have had cryptococcal meningitis should continue until CD4 count remains >200 cells/µL.  Patients on isoniazid TB prophylaxis who start ARVs should complete isoniazid treatment.

Adherence

Adherence Overview  Treatment success depends on tablet-taking behavior.  Ideal adherence means patient takes >95% of doses.  Should miss <3 doses/month  If patient is taking <95% of doses:  Increased risk of developing viral resistance  Decreased viral suppression  Increased risk of long-term treatment failure

Adherence Overview (cont.)  Difficult to predict which patients will be adherent.  Important to provide all patients with a comprehensive plan that utilizes multiple strategies to support adherence.  Involve members of the health care team, family, and community in developing plan.

Strategies to Promote Adherence  Spend time with patients and have several meetings to explain goals of therapy.  Negotiate treatment plans that patients can understand.  Provide tools such as calendar of medications and pillboxes.  Ask patients about other medications they may be taking.  Develop links with community-based organizations to support adherence.  eg, home-based care organizations

Pretreatment: Promoting Adherence before Starting ART  Give patients pretreatment information and education per visit schedule.  Introduce patients to therapeutic counselor and patient advocate.  Do cotrimoxazole pill count for 1 month prior to commencing ART.  This reinforces daily medication-taking behavior and helps identify potential problems before starting ART.

At Each Treatment Visit:  Do ARV tablet count to calculate adherence.  (Ideal, but depends on clinic staff and workload)  Goal: >95% doses taken  Patient with adherence <80% requires additional support  Tablet count may done before patient is seen by doctor  Address missed/late appointments.  Evaluate for possible side effects of treatment and manage appropriately.  Allow time for questions with therapeutic counselor.  Encourage participation in a support group.  Arrange regular community visits by patient advocates.

Additional Adherence Support  Additional adherence support is needed when adherence is <80% with or without viral or clinical failure.  Therapeutic counselor/nurse or doctor must reeducate patient.  Emphasize long-term benefits of treatment.  Supply memory aids such as pillboxes or daily dosing diaries.  Insist on participation in a support group.  Check family situation.  Check psychological profile of patient.  Increase home visits by counselors or patient advocates.  Consider directly observed therapy for a specific amount of time.

Calculating Monthly Adherence  Monthly adherence = (tablets dispensed - tablets returned) / (tablets prescribed)  30-5/28 = 25/28  25/28 = 0.9  0.9 x 100% = 90%  Adjust for actual number of days in a given month

Clinical and Laboratory Monitoring

Types of Clinical/Lab Monitoring Monitoring for:  Side effects  Treatment failure (viral load, CD4 count) Common tests for monitoring side effects:  FBC (full blood count): to test for anemia from zidovudine (ZDV)  ALT: to test liver function  Triglycerides, fasting cholesterol, fasting glucose: to test for elevated cholesterol levels from protease inhibitors

Routine Monitoring for Regimen 1

Routine Monitoring for Regimen 2

Clinical and Laboratory Monitoring for Patients on Regimen 1a or 1b  Patients attend monthly to collect medications.  Seen by a professional nurse to monitor drug tolerance, adverse events, and adherence.  If possible, have clinic nurse, doctor, pharmacist, or therapeutic counselor count drugs.  Patients should be seen by doctor at 4, 8, and 12 weeks, and every 3 months thereafter.  CD4 count and viral load measured every 6 months.  If patient is not doing well, see patient more frequently as determined by doctor or nurse.

Special Monitoring for Patients on Regimen 1b  Patients need to be seen by nurse at 2 weeks of treatment.  In addition to monthly visits, to check for adverse effects.  Need to check ALT levels at baseline; at 2, 4, and 8 weeks; and every 6 months thereafter.  Adjust dosing as needed.

Clinical and Laboratory Monitoring for Patients on Regimen 2  Patients must come in monthly for first 3 months to see doctor.  Thereafter, must see doctor every 6 months or as required.  Drugs should be collected every month.

Special Monitoring for Patients on Regimen 2  There is no viral load monitoring for patients in regimen 2.  FBC will be measured monthly for 3 months and every 6 months thereafter.  In addition, monitor for elevated cholesterol. Check:  Fasting cholesterol  Triglycerides  Fasting glucose

Viral Load Monitoring If viral load is <400 copies/mL:  Monitor viral load every 6 months  Provide routine adherence support

Viral Load Monitoring (cont.) If viral load count is 400 to 5,000 copies/mL:  Repeat viral load check in 6 months.  Begin stepped-up adherence package. Review at next 6- month viral load check.  If <400 copies/mL, return to monitoring at 6-month intervals and resume adherence support.  If still between 400 and 5,000 copies/mL, continue stepped- up adherence package, repeat viral load check at 6 months.  If >5,000 copies/mL despite stepped up adherence support, switch to second-line therapy only if adherence is >80%.

Viral Load Monitoring (cont.) If viral load count is >5,000 copies/mL:  Repeat viral load check in 3 months.  Begin stepped-up adherence package. Review at next 6- month viral load check.  If <400 copies/mL, return to monitoring at 6-month intervals and resume adherence support.  If between 400 and 5,000 copies/mL, continue stepped-up adherence package, repeat viral load check at 6 months.  If >5,000 copies/mL despite stepped-up adherence support, switch to second-line therapy only if adherence is >80%.

Unscheduled Visits  Assess whether additional safety bloods are required if patient presents with adverse event.  No extra CD4 count or viral load test should be performed.  Only exception is when repeating viral load test after previous count of >5,000 copies/mL.

Treatment Failure  Patients who experience virologic failure on regimen 1 despite adherence may be changed to regimen 2.  Prior to changing, patients should undergo readiness and education process again.  Determine whether patients are hiding their nonadherence.  Patients who experience failure on regimen 2 should receive increased adherence support.

Treatment Failure with Regimen 2  If failure occurs despite demonstrated adherence, continue ARVs until the patient ceases to derive any clinical benefit from treatment.  If adherence is consistently <80%, the patient requires ongoing education and counseling.  If the patient has a WHO Stage IV illness on regimen 2, consult with an expert about stopping therapy and starting palliative care.